Catheterbased REnal SympatheCtomy for hypErteNsion after kidneyTranplantation - CRESCENT Study

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•renal graft in situ since > 6 months, measured creatinine clearance > 35 ml/min, and - diuresis of the native kidneys at transplant >200 ml/day or radiological evidence of residual flow in the renal arteries indicating that they are accessible for the intervention and - day time blood pressure >140/90 mmHg (assessed by 24-hours ambulatory measurement within 3 month prior to inclusion in the study, as is regularly performed in the nephrology outpatient clinic) while - treated according to National Kidney Foundation Kidney Disease Quality Outcomes Quality Initiative guidelines (2004), i.e. having been advised to minimize salt intake and using >3 antihypertensive medications in maximal tolerated dose, including a diuretic or using *4 antihypertensive medications in any dosage. Medications and their dosages should not have been changed since the measurement.

•- (planned) pregnancy, lactation - life expectancy < 1 year - non-functioning renal allograft in situ - contraindications for (relative) hypotensive episodes i.e. haemodynamically significant valvular disease, documented transient ischemic attacks or angina pectoris during relative hypotension. - heart failure, NYHA class III-IV; chronic Lung Disease Gold III-IV - major complications during previous radiological interventions (i.e. allergy to contrast agent, cholesterol embolism) - (reno) vascular abnormalities in any part of the catheter access (including the aortic-ileac tract) route that impede the procedure of renal denervation - use of vitamine K antagonists or other (non-aspirin) form of anti-coagulatory therapy with an absolute indication (i.e. that cannot be temporarily stopped) - implantable cardioverter defibrillator (ICD) in situ - planned surgery within the next six months. - Drugs- or alcohol abuse - Inability to give informed consent

发起方